Last reviewed · How we verify
FOLFOX induction regimen
Oxaliplatin inhibits DNA replication by binding to DNA and inducing DNA damage.
Oxaliplatin inhibits DNA replication by binding to DNA and inducing DNA damage. Used for Colorectal cancer.
At a glance
| Generic name | FOLFOX induction regimen |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Oxaliplatin is a platinum-based chemotherapy drug that works by cross-linking DNA, thereby inhibiting DNA replication and transcription. This leads to cell death, particularly in rapidly dividing cancer cells.
Approved indications
- Colorectal cancer
Common side effects
- Neutropenia
- Diarrhea
- Nausea
- Vomiting
- Fatigue
Key clinical trials
- Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity (PHASE2, PHASE3)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer (PHASE2)
- Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status (PHASE4)
- A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue (PHASE2)
- Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy (EARLY_PHASE1)
- Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management (PHASE2)
- Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FOLFOX induction regimen CI brief — competitive landscape report
- FOLFOX induction regimen updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI